DEF: Hologic Reports Strong Fiscal Year 2024 Performance, Driven by Core Business Growth

Hologic delivered solid fiscal year 2024 results, achieving revenue growth in core businesses and demonstrating strong profitability and cash flow.

Summary

• Hologic's fiscal year 2024 saw a return to top-line revenue growth in the third and fourth quarters, with total revenue of $4.03 billion.
• The company's core business is now 30% larger than in 2019, with more diverse and durable revenue streams.
• Adjusted gross margin was 61%, and adjusted operating margin was 30%, showcasing industry-leading profitability.
• Operating cash flow reached nearly $1.3 billion in fiscal 2024, and the company ended the year with approximately $2.4 billion in cash and investments.
• Hologic reduced its leverage ratio from 4.0x to 0.3x over the past 10 years and lowered its share count by nearly 31 million shares over the past 5 years.
• Adjusted EPS has grown at a compound annual growth rate of over 10% since 2014.
• The Diagnostics business grew 5.9% organically, excluding COVID-19 revenues, with Molecular diagnostics growing 9.0%.
• Breast Health revenue grew 6.8% organically, excluding the divested SSI ultrasound imaging business and the Endomagnetics acquisition.
• The Surgical business saw revenue growth of 5.9% in constant currency, driven by the MyoSure business and international growth of over 20%.

Sentiment

Score: 8

Explanation: The document conveys a strong positive sentiment, highlighting significant financial achievements, strategic growth, and a commitment to social initiatives. The language is optimistic and confident, reflecting a positive outlook for the company's future.

Positives

• Hologic successfully returned to top-line total company reported revenue growth in both the third and fourth quarters of fiscal 2024.
• The company's core business is now 30% larger compared to 2019, with more diverse and durable revenue streams.
• Hologic has reduced its leverage ratio from 4.0x to 0.3x over the past 10 years.
• The company has lowered its share count by nearly 31 million shares over the past 5 years.
• Hologic is well positioned to grow EPS at a faster rate than revenue over the long term.
• The company received FDA approval for its Genius Digital Diagnostics system.
• Hologic unveiled its next-generation Envision mammography platform in December 2024.
• The company has a peer group leading cash flow.
• Hologic continues to invest in social initiatives, such as the Hologic Global Womens Health Index.
• Fortune recognized Hologic as one of the top 15 large companies in healthcare to work for in 2024.

Negatives

• COVID-19 testing revenue is expected to continue to decline in fiscal 2025.
• The company moved past a global semiconductor chip shortage, which impacted mammography system production.

Risks

• The document mentions the expectation of continued decline in COVID-19 testing revenue in fiscal 2025.
• The document references an uncertain macroeconomic and geopolitical environment.

Future Outlook

Hologic anticipates strong core business growth to continue driving top-line growth in fiscal 2025, despite expected declines in COVID-19 testing revenue. The company expects gross margins in the low 60s and operating margins in the low 30s for fiscal 2025.

Management Comments

• Fiscal 2024 was another good year for Hologic, as we continued to build on our strong foundation.
• Our teams around the world again delivered exceptional performance fueling significant growth.
• We delivered on our financial and operational commitments and reaffirmed our core philosophy to provide the best technologies and services for our customers and patients.
• We are proud of our progress and excited about the future and strength of our business as we look ahead.
• We are committed to delivering exceptional products and services for the women of the world, and strong financial results for our stockholders.

Industry Context

Hologic's focus on women's health aligns with a growing global emphasis on preventative care and early detection of diseases. The company's expansion into new end markets and commercial capabilities positions it well to capitalize on these trends. The company's focus on innovation, particularly in AI-powered diagnostics, reflects a broader industry shift towards advanced technologies.

Comparison to Industry Standards

• Hologic's adjusted gross margin of 61% and adjusted operating margin of 30% are described as 'best-in-class', suggesting they are at the higher end of the range for medical technology companies.
• The company's strong cash flow generation, with nearly $1.3 billion in operating cash flow, is described as 'peer group leading', indicating it is among the top performers in its industry.
• The document highlights Hologic's market-leading position in mammography, with 3D technology that provides higher quality imaging, a more comfortable patient experience, and enhanced workflow for technicians, suggesting a competitive advantage over other players in the mammography market.
• The company's international surgical business growth of more than 20% in constant currency indicates a strong performance compared to industry averages for international expansion.
• The document mentions that Hologic has grown adjusted EPS at a compound annual growth rate of over 10% since 2014, which is a strong performance compared to many other companies in the medical technology sector.

Management Changes

Corporate Governance

Related Party Transactions

• Peter Wells, the stepson of Sally Crawford, a member of our Board, is employed by the Company as an IT Business Analyst. He earned approximately $192,000 in total annual compensation during fiscal 2024.

Stakeholder Impact

• Shareholders will benefit from the company's strong financial performance, share repurchases, and potential for future growth.
• Employees will benefit from a positive work environment and recognition as a top healthcare employer.
• Customers and patients will benefit from the company's commitment to providing the best technologies and services.
• The company's social initiatives, such as the Hologic Global Womens Health Index, will benefit women globally by raising awareness of health disparities and driving policy change.

Next Steps

• Hologic will continue to invest in organic growth priorities.
• The company will pursue additional M&A opportunities.
• Hologic will deliver value to shareholders.
• The company will release the fourth annual findings of the Hologic Global Womens Health Index at the World Economic Forum in late January 2025.

Key Dates

Keywords

Hologic, womens health, diagnostics, breast health, surgical, revenue growth, profitability, cash flow, mammography, molecular diagnostics, acquisitions, share repurchase, Envision, Genius Digital Diagnostics, Panther system